ArticleFrontiers in endocrinology2025
FSH receptor N680S genotype-guided gonadotropin choice increases cumulative pregnancy and live birth rates after
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Urinary and Recombinant Follicle-Stimulating Hormone in Supporting Primate Follicular Development In Vitro.Current issues in molecular biology · 2026Article
- FSH Receptor Asn680Ser Polymorphism Modulates Intrafollicular Nitric Oxide Bioavailability and Ovarian Responsiveness During IVF.International journal of molecular sciences · 2026Article
- Significance of Follicle-Stimulating Hormone Receptor Gene Single-Nucleotide Polymorphism rs6165/rs6166 Analysis for Infertility-Associated Ovarian Disease Susceptibility Prediction and Optimized Individualized Ovulation Induction/Ovarian Stimulation.Diagnostics (Basel, Switzerland) · 2026Review
- A point-of-care assay for genotyping women prior to ovarian stimulation with recombinant or human menopausal gonadotropins in assisted reproduction.Frontiers in endocrinology · 2026Article
- Commentary: FSH receptor N680S genotype-guided gonadotropin choice increases cumulative pregnancy and live birth rates afterFrontiers in endocrinology · 2025Article
- Metabolic state and female fertility in ART cycles: a summary of current advances.Frontiers in cell and developmental biology · 2025Review
- The Asn680Ser Variant Negatively Impacted the Ovarian Response to Controlled Ovarian Stimulation in Thai Female Infertility.In vivo (Athens, Greece)Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to compare cumulative [fresh and frozen embryo transfers from one ovarian stimulation (OS) cycle] pregnancy and live birth rates in women for whom the choice between recombinant FSH (rFSH) and urinary FSH (uFSH) for OS was linked to FSH receptor (FSHR) N680S genotype and compared these to non-genotyped controls. Methods: To define the optimal combination of FSH type and FSHR genotype, 475 women were allocated to either the rFSH group or to the uFSH group for OS. The number of aspirated oocytes, cumulative pregnancy rates, and live birth rates in the first OS cycle were determined. Subsequently, their FSHR N680S (rs6166) variant was analyzed. Clinical data were backed up by Results: The combined clinical and Conclusion: A significantly increased chance of pregnancy and live birth can be achieved by a genotype-guided approach. While the administration of uFSH should be the choice for S-carriers, rFSH is beneficial for NN-carrying women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.